All Title Author
Keywords Abstract

PLOS ONE  2011 

Conditional Gene Expression in Mycobacterium abscessus

DOI: 10.1371/journal.pone.0029306

Full-Text   Cite this paper   Add to My Lib


Mycobacterium abscessus is an emerging human pathogen responsible for lung infections, skin and soft-tissue infections and disseminated infections in immunocompromised patients. It may exist either as a smooth (S) or rough (R) morphotype, the latter being associated with increased pathogenicity in various models. Genetic tools for homologous recombination and conditional gene expression are desperately needed to allow the study of M. abscessus virulence. However, descriptions of knock-out (KO) mutants in M. abscessus are rare, with only one KO mutant from an S strain described so far. Moreover, of the three major tools developed for homologous recombination in mycobacteria, only the one based on expression of phage recombinases is working. Several conditional gene expression tools have recently been engineered for Mycobacterium tuberculosis and Mycobacterium smegmatis, but none have been tested yet in M. abscessus. Based on previous experience with genetic tools allowing homologous recombination and their failure in M. abscessus, we evaluated the potential interest of a conditional gene expression approach using a system derived from the two repressors system, TetR/PipOFF. After several steps necessary to adapt TetR/PipOFF for M. abscessus, we have shown the efficiency of this system for conditional expression of an essential mycobacterial gene, fadD32. Inhibition of fadD32 was demonstrated for both the S and R isotypes, with marginally better efficiency for the R isotype. Conditional gene expression using the dedicated TetR/PipOFF system vectors developed here is effective in S and R M. abscessus, and may constitute an interesting approach for future genetic studies in this pathogen.


[1]  Brown-Elliott BA, Wallace RJ Jr (2002) Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15: 716–746.
[2]  Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C (2008) Spectrum of CNS disease caused by rapidly growing mycobacteria. Lancet Infect Dis 8: 390–398.
[3]  Wallace RG Jr, Silcox V, Brown BA (1994) Taxonomy of rapidly growing mycobacteria. Clin Infect Dis 18: 121–122.
[4]  J?nsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, et al. (2007) Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol 45: 1497–1504.
[5]  Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, et al. (2009) Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 47: 4124–4128.
[6]  Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, Offredo C, Guillemot D, et al. (2003) Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 9: 1587–1591.
[7]  Feldman EM, Ellsworth W, Yuksel E, Allen S (2009) Mycobacterium abscessus infection after breast augmentation: a case of contaminated implants? J Plast Reconstr Aesthet Surg 62: e330–332.
[8]  Newman MI, Camberos AE, Clynes ND, Ascherman JA (2005) Outbreak of atypical mycobacteria infections in U.S. Patients traveling abroad for cosmetic surgery. Plast Reconstr Surg 115: 964–965.
[9]  Garcia-Navarro X, Barnadas MA, Dalmau J, Coll P, Gurgui M, et al. (2008) Mycobacterium abscessus infection secondary to mesotherapy. Clin Exp Dermatol 33: 658–659.
[10]  Medjahed H, Gaillard JL, Reyrat JM (2010) Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol.
[11]  Cullen AR, Cannon CL, Mark EJ, Colin AA (2000) Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 161: 641–645.
[12]  Catherinot E, Roux AL, Macheras E, Hubert D, Matmar M, et al. (2009) Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 47: 271–274.
[13]  Rottman M, Catherinot E, Hochedez P, Emile JF, Casanova JL, et al. (2007) Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect Immun 75: 5898–5907.
[14]  Byrd TF, Lyons CR (1999) Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect Immun 67: 4700–4707.
[15]  Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile JF, et al. (2007) Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 75: 1055–1058.
[16]  Roux AL, Ray A, Pawlik A, Medjahed H, Etienne G, et al. (2010) Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants. Cell Microbiol.
[17]  Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, et al. (2009) Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 4: e5660.
[18]  Medjahed H, Reyrat JM (2009) Construction of Mycobacterium abscessus defined glycopeptidolipid mutants: comparison of genetic tools. Appl Environ Microbiol 75: 1331–1338.
[19]  Pelicic V, Jackson M, Reyrat JM, Jacobs WR Jr, Gicquel B, et al. (1997) Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 94: 10955–10960.
[20]  Bardarov S, Kriakov J, Carriere C, Yu S, Vaamonde C, et al. (1997) Conditionally replicating mycobacteriophages: a system for transposon delivery to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 94: 10961–10966.
[21]  van Kessel JC, Hatfull GF (2007) Recombineering in Mycobacterium tuberculosis. Nat Methods 4: 147–152.
[22]  Parish T, Mahenthiralingam E, Draper P, Davis EO, Colston MJ (1997) Regulation of the inducible acetamidase gene of Mycobacterium smegmatis. Microbiology 143 ( Pt 7): 2267–2276.
[23]  Blokpoel MC, Murphy HN, O'Toole R, Wiles S, Runn ES, et al. (2005) Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res 33: e22.
[24]  Carroll P, Muttucumaru DG, Parish T (2005) Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol 71: 3077–3084.
[25]  Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, et al. (2005) Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33: e21.
[26]  Guo XV, Monteleone M, Klotzsche M, Kamionka A, Hillen W, et al. (2007) Silencing Mycobacterium smegmatis by using tetracycline repressors. J Bacteriol 189: 4614–4623.
[27]  Klotzsche M, Ehrt S, Schnappinger D (2009) Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res 37: 1778–1788.
[28]  Forti F, Crosta A, Ghisotti D (2009) Pristinamycin-inducible gene regulation in mycobacteria. J Biotechnol 140: 270–277.
[29]  Pandey AK, Raman S, Proff R, Joshi S, Kang CM, et al. (2009) Nitrile-inducible gene expression in mycobacteria. Tuberculosis (Edinb) 89: 12–16.
[30]  Boldrin F, Casonato S, Dainese E, Sala C, Dhar N, et al. (2010) Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res 38: e134.
[31]  Brown BA, Wallace RJ Jr, Onyi G (1996) Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deo?xytetracyclineagainst Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother 40: 874–878.
[32]  Portevin D, de Sousa-D'Auria C, Montrozier H, Houssin C, Stella A, et al. (2005) The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J Biol Chem 280: 8862–8874.
[33]  Ordway D, Henao-Tamayo M, Smith E, Shanley C, Harton M, et al. (2008) Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol 83: 1502–1511.
[34]  Zhang Y, Yakrus MA, Graviss EA, Williams-Bouyer N, Turenne C, et al. (2004) Pulsed-field gel electrophoresis study of Mycobacterium abscessus isolates previously affected by DNA degradation. J Clin Microbiol 42: 5582–5587.
[35]  Serafini A, Boldrin F, Palu G, Manganelli R (2009) Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc. J Bacteriol 191: 6340–6344.
[36]  Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW (2002) Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 46: 3164–3167.
[37]  Ripoll F, Deshayes C, Pasek S, Laval F, Beretti JL, et al. (2007) Genomics of glycopeptidolipid biosynthesis in Mycobacterium abscessus and M. chelonae. BMC Genomics 8: 114.
[38]  Snapper SB, Melton RE, Mustafa S, Kieser T, Jacobs WR Jr (1990) Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol 4: 1911–1919.
[39]  Daffé M, Draper P (1998) The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39: 131–203.
[40]  Cortes MA, Nessar R, Singh AK (2010) Laboratory maintenance of Mycobacterium abscessus. Curr Protoc Microbiol Chapter 10: Unit 10D 11:
[41]  Medjahed H, Singh AK (2010) Genetic manipulation of Mycobacterium abscessus. Curr Protoc Microbiol Chapter 10: Unit 10D 12:
[42]  Miller JH (1992) A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria. Press CSHL, editor. New York. 876 p.
[43]  Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, et al. (2007) Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35: W71–74.
[44]  Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
[45]  Gao LY, Groger R, Cox JS, Beverley SM, Lawson EH, et al. (2003) Transposon mutagenesis of Mycobacterium marinum identifies a locus linking pigmentation and intracellular survival. Infect Immun 71: 922–929.
[46]  Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456–460.


comments powered by Disqus